Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Jose Lopez Puebla

Hematology & Oncology San Juan, PR Medical Doctor

NPI 1659828473 CMS profile 7905165

Upr School Of Medicine Medical Science Campus, Guillermo Arbona Building, San Juan, PR 00936

Open in the dashboard

General payments

$12,151

524 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jose Lopez Puebla of San Juan, PR is reported in the CMS Open Payments database as having received $12,151 across 524 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,129 176
2024 General $3,723 160
2023 General $1,957 88
2022 General $1,126 51
2021 General $1,172 46
2020 General $44 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jose Lopez Puebla
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Jose Lopez Puebla were reported at $4,129. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Jose Lopez Puebla Hematology & Oncology median Middle half National median
2019 $0 $529 $121–$2,516 $163
2020 $44 $339 $82–$2,213 $114
2021 $1,172 $263 $49–$1,965 $132
2022 $1,126 $416 $103–$2,395 $149
2023 $1,957 $542 $125–$2,646 $160
2024 $3,723 $692 $141–$3,008 $164
2025 $4,129 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. AstraZeneca Pharmaceuticals LP $1,416 65 payments
  2. Janssen Pharmaceuticals, Inc $1,409 65 payments
  3. E.R. Squibb & Sons, L.L.C. $1,061 46 payments
  4. Merck Sharp & Dohme Corporation $960 46 payments
  5. PBG Puerto Rico LLC $949 44 payments
  6. AbbVie, Inc. $854 33 payments
  7. Genentech USA, Inc. $761 37 payments
  8. Amgen Inc. $699 34 payments
  9. Novartis Pharmaceuticals Corporation $532 24 payments
  10. Bayer Puerto Rico Inc. $446 19 payments
  11. Other $3,063 111 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $11,521 516 payments
  2. Education $630 8 payments
Products named General payments · program years 2020–2025
  1. KEYTRUDA $939 45 payments
  2. VENCLEXTA $714 27 payments
  3. OPDIVO $654 28 payments
  4. DARZALEX $631 26 payments
  5. XGEVA $550 27 payments
  6. ERLEADA $484 18 payments
  7. Nubeqa $469 20 payments
  8. XTANDI $462 18 payments
  9. Stivarga $444 19 payments
  10. IBRANCE $440 20 payments
  11. Other $11,228 508 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

438

Median for Hematology-Oncology: 604

Drug cost

$533,250

Median for Hematology-Oncology: $1,306,514

Branded share of claims

42.7%

Median for Hematology-Oncology: 31.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtandi Enzalutamide Brand 16 $230,949
Erleada Apalutamide Brand 15 $223,243
Fulphila Pegfilgrastim-Jmdb Brand 13 $27,446
Eliquis Apixaban Brand 41 $25,678
Tranexamic Acid Generic 25 $10,962
Retacrit Epoetin Alfa-Epbx Brand 15 $6,616
Fentanyl Generic 17 $1,862
Dexamethasone Generic 35 $1,337
Tramadol Hcl-Acetaminophen Tramadol Hcl/Acetaminophen Brand 32 $1,254
Ondansetron Odt Ondansetron Brand 24 $1,144

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 62 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KEYTRUDA
  • Merck Sharp & Dohme Corporation $311
$311 — —
OPDIVO
  • E.R. Squibb & Sons, L.L.C. $253
$253 — —
DARZALEX
  • Janssen Pharmaceuticals, Inc $164
$164 — —
XTANDI
  • PFIZER INC. $89
  • PBG PUERTO RICO LLC $70
$159 16 —
LYNPARZA
  • AstraZeneca Pharmaceuticals LP $154
$154 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 62 with Patron

Records

524 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record